15Jul/13

Curis' Differentiated Oncology Approach Is Worth More Than The Market Suggests – Seeking Alpha

Curis’ Differentiated Oncology Approach Is Worth More Than The Market Suggests
Seeking Alpha
Idelalisib generated a complete response rate of 19% and an overall response rate of 97% when combined with rituximab in treatment-naive older patients with chronic lymphocytic leukemia. And Infinity, at the meeting of the American Society for Clinical 

and more »

15Jul/13

Stocks in Focus: Windstream Corporation, Yahoo! Inc.(NASDAQ:YHOO … – US Market Buzz

Stocks in Focus: Windstream Corporation, Yahoo! Inc.(NASDAQ:YHOO
US Market Buzz
idelalisib (formerly GS-1101), an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin’s lymphoma (iNHL) that is refractory (non-responsive) to rituximab and to alkylating-agent-containing

and more »

15Jul/13

Autism can be tied to maternal antibodies – West – Welfare Society Territory


West – Welfare Society Territory

Autism can be tied to maternal antibodies
West – Welfare Society Territory
Autism could be linked to the action of some maternal antibodies during gestation. That, by penetrating the placenta, affect fetus’ brain development. This is the result of a study carried out by the University of Davis in California and published in
UC Davis study finds connection between mother’s antibodies, autismDaily Democrat
Newly Discovered Antibodies Produced by Some Pregnant Women May Lead to Growing Your Baby
Antibody clue to autism in childrenBusiness Recorder (blog)
San Francisco Chronicle (blog) –CTV News
all 4 news articles »
15Jul/13

LI-COR VRDye Secondary Antibodies for Microscopy and Flow Cytometry Now … – SelectScience.net (press release)

LI-COR VRDye Secondary Antibodies for Microscopy and Flow Cytometry Now
SelectScience.net (press release)
LI-COR offers VRDye™ secondary antibodies and protein labeling kits for immunofluorescence microscopy and flow cytometry applications. The VRDye products broaden LI-COR’s dye product portfolio, which now spans from the visible to the near-infrared